Valsartan — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hypertension

• Amlodipine
• Atenolol
• Bisoprolol
• Carvedilol
• Diltiazem
• Furosemide
• Hydrochlorothiazide
• Lisinopril

Other medications in Heart & Cardiovascular

• Verapamil
• Verapamil IV
• Vernakalant
• Vorapaxar
• Warfarin
• Adenosine
• Alirocumab
• Ambrisentan

What Valsartan is approved for (FDA label)

Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of heart failure (NYHA class II-IV); valsartan tablets significantly reduced hospitalization for heart failure. ( 1.2 ) Post-myocardial infarction; for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction. ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: September 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Valsartan (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue valsartan tablets as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue valsartan tablets as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 5a816ea6-2645-bd6e-e063-6294a90a908b. SPL document ID: 5a816ba8-afd9-bda3-e063-6294a90a16bb. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Valsartan (FDA label)

40 mg are yellow, oval, film-coated scored tablets debossed with ”3” bisect “7” on one side and “AN” on the other side. 80 mg are pink, oval, film-coated tablets with beveled edges, debossed with ”838” on one side and ”AN” on the other side. 160 mg are yellow, oval, film-coated tablets with beveled edges, debossed with ”839” on one side and “AN” on the other side. 320 mg are brown, oval, film-coated tablets with beveled edges, debossed with ”840” on one side and “AN” on the other side. Tablets (mg): 40 (scored), 80, 160, 320

Source: FDA prescribing information (DailyMed). Set ID: 5a816ea6-2645-bd6e-e063-6294a90a908b. SPL document ID: 5a816ba8-afd9-bda3-e063-6294a90a16bb. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Valsartan (FDA label)

Hypertension: Most common adverse reactions are headache, dizziness, viral infection, fatigue and abdominal pain. (6.1) Heart Failure: Most common adverse reactions are dizziness, hypotension, diarrhea, arthralgia, back pain, fatigue and hyperkalemia. (6.1) Post-Myocardial Infarction: Most common adverse reactions which caused patients to discontinue therapy are hypotension, cough and increased blood creatinine. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 5a816ea6-2645-bd6e-e063-6294a90a908b. SPL document ID: 5a816ba8-afd9-bda3-e063-6294a90a16bb. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Valsartan (FDA label)

Do not use in patients with known hypersensitivity to any component. Do not co-administer aliskiren with valsartan tablets in patients with diabetes [see Drug Interactions (7) ] . Known hypersensitivity to any component. Do not co-administer aliskiren with valsartan tablets in patients with diabetes. (4)

Source: FDA prescribing information (DailyMed). Set ID: 5a816ea6-2645-bd6e-e063-6294a90a908b. SPL document ID: 5a816ba8-afd9-bda3-e063-6294a90a16bb. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Valsartan (FDA label)

Observe for signs and symptoms of hypotension. (5.2) Monitor renal function and potassium in susceptible patients. (5.3, 5.4) 5.1 Fetal Toxicity Valsartan tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue valsartan as soon as possible [see Use in Specific Populations (8.1) ] . 5.2 Hypotension Excessive hypotension was rarely seen (0.1%) in patients with uncomplicated hypertension treated with valsartan alone. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur.

Source: FDA prescribing information (DailyMed). Set ID: 5a816ea6-2645-bd6e-e063-6294a90a908b. SPL document ID: 5a816ba8-afd9-bda3-e063-6294a90a16bb. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Valsartan (FDA label)

Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine. (7.1) NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect. (7.2) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. (7.3) Lithium: Increases in serum lithium level and lithium toxicity. (7.4) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.

Source: FDA prescribing information (DailyMed). Set ID: 5a816ea6-2645-bd6e-e063-6294a90a908b. SPL document ID: 5a816ba8-afd9-bda3-e063-6294a90a16bb. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.